Skip to main content

Advertisement

SpringerLink
Log in

A robust estimation of infliximab pharmacokinetic parameters in Crohn’s disease

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33(7):946–964

    Article  CAS  PubMed  Google Scholar 

  2. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211–1228

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523–529

    CAS  PubMed  Google Scholar 

  4. Ternant D, Berkane Z, Picon L, Gouilleux-Gruart V, Colombel JF, Allez M, Louis E, Paintaud G (2014) Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn’s disease. Clin Pharmacokinet 2014:17

    Google Scholar 

  5. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G (2006) An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 28(2):169–174

    Article  CAS  PubMed  Google Scholar 

  6. Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, Ben Yehoyada M, Mould DR (2014) Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 20(12):2247–2259

    Article  PubMed  Google Scholar 

  7. Ternant D, Ducourau E, Perdriger A, Corondan A, Le Goff B, Devauchelle-Pensec V, Solau-Gervais E, Watier H, Goupille P, Paintaud G, Mulleman D (2013) Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 2013(19):12313

    Google Scholar 

  8. Ternant D, Mulleman D, Lauferon F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G (2011) Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2011(22):1365–2125

    Google Scholar 

  9. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H (2008) Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 48(6):681–695

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Measurements of infliximab serum concentrations were carried out within the CePiBAc platform. CePiBAc was cofinanced by the European Union. Europe is committed to the region center with the European Regional Development Fund. This work was partly supported by the French Higher Education and Research ministry under the program ‘Investissements d’avenir’ Grand Agreement: LabEx MAbImprove ANR-10-LABX-53-01. The authors would like to thank Dr. Charlotte Magdelaine, Prof. Hervé Watier, and Dr. Danielle Degenne for the ATI assay management and Anne-Claire Duveau, Caroline Brochon, and Audrey Farnault for the technical assistance with infliximab and ATI assays.

Contribution of authors statement

D. Aubourg analyzed and interpreted the data and wrote the manuscript; Dr. Picon participated actively in execution of the study; Dr. Lecomte participated in the execution of the study; Dr. Paintaud participated in the interpretation of the data in manuscript writing; Dr. Paintaud participated in the interpretation of the data in manuscript writing; Dr Ternant participated in the data analysis, interpretation, and in manuscript writing.

Conflict of interest

Dr. Paintaud reports grants from Novartis, grants from Roche Pharma, grants from Genzyme, grants from MSD, grants from Servier, grants from Pfizer, outside the submitted work.

Dr. Aubourg, Dr Picon, Dr. Lecomte, Dr. Bejan-Angoulvant and Dr. Ternant declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Service de Gastroentérologie, CHRU de Tours, Tours, France

    Alexandre Aubourg, Laurence Picon & Thierry Lecomte

  2. Université François-Rabelais de Tours, CNRS, GICC UMR 7292, Tours, France

    Thierry Lecomte, Theodora Bejan-Angoulvant, Gilles Paintaud & David Ternant

  3. Service de Pharmacologie, CHRU de Tours, Tours, France

    Theodora Bejan-Angoulvant

  4. Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, 2 boulevard Tonnellé, 37044, Tours Cedex, France

    Gilles Paintaud & David Ternant

Authors
  1. Alexandre Aubourg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Picon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thierry Lecomte
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Theodora Bejan-Angoulvant
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gilles Paintaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David Ternant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Ternant.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aubourg, A., Picon, L., Lecomte, T. et al. A robust estimation of infliximab pharmacokinetic parameters in Crohn’s disease. Eur J Clin Pharmacol 71, 1541–1542 (2015). https://doi.org/10.1007/s00228-015-1942-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-015-1942-8

Keywords

Search

Navigation